Soleno Therapeutics, Inc. announced that it has initiated a randomized withdrawal period of Study C602, an ongoing open-label extension study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS). The randomized withdrawal period of Study C602 is a multi-center, randomized, double-blind, placebo-controlled study of DCCR in approximately 80 patients with PWS at 17 sites in the U.S. and 5 sites in the U.K. This randomized withdrawal period consists only of patients currently enrolled in Study C602 and will not enroll any new patients. Upon Institutional Review Board/Ethics approvals at their respective sites, patients who consent to participate in the randomized withdrawal period, will be randomized to receive DCCR or placebo for a period of four months.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.41 USD | -5.80% | -6.91% | +5.37% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.37% | 1.54B | |
+18.15% | 124B | |
+18.02% | 112B | |
-12.75% | 22.22B | |
+5.07% | 22.94B | |
-39.94% | 16.87B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- SLNO Stock
- News Soleno Therapeutics, Inc.
- Soleno Therapeutics, Inc. Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome